Matthew C. Abernethy
Chief Financial OfficerMr. Matthew C. Abernethy, also known as Matt, C.P.A., serves as Independent Director of Fate Therapeutics, Inc. from May 29, 2025. Mr. Abernethy has been the Chief Financial Officer at Neurocrine Biosciences, Inc. since November 29, 2017. Mr. Abernethy has experience in the financial sector and investor relations with expertise in the healthcare industry. Mr. Abernethy served as the Principal Financial Officer and Vice President of Global Finance at Biomet Orthopedics, LLC and Biomet U.S. Reconstruction, LLC. Mr. Abernethy served as Vice President of Investor Relations and Treasurer of Zimmer Biomet Holdings, Inc. until November 2017. He joined Neurocrine from Zimmer Biomet, where he held various positions from February 2009 to November 2017, over the past nine years including Vice President of Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr. Abernethy earned his B.S. in Accounting and Business Administration from Grace College and an MBA from the University of Chicago.
公司职务
- 公司名称Neurocrine Biosciences, Inc.股票代码NBIX职务Chief Financial Officer共事同僚
- KWKyle W. GanoPresident, CEO & Director
- WHWilliam H. RastetterIndependent Chairman of the Board
- MCMatthew C. AbernethyChief Financial Officer
- JOJude OnyiaChief Scientific Officer
- ESEric S. BenevichChief Commercial Officer
- EWEiry Wyn RobertsChief Medical Officer
- RFRichard F. PopsIndependent Director
- LVLeslie V. NorwalkIndependent Director
- SSShalini SharpIndependent Director
- 公司名称Fate Therapeutics, Inc.股票代码FATE职务Independent Director共事同僚
- BVBahram ValamehrPresident, CEO & Director
- WHWilliam H. RastetterIndependent Chairman
- KAKamal AdawiCFO & Treasurer
- CRCindy R. TahlChief Legal & Compliance Officer and Corporate Secretary
- JFJessica FrancisSenior Vice President of Human Resources & Operations
- MHMartin HoskingHead of Research
- RSRobert S. EpsteinIndependent Director
- KJKarin JoossIndependent Director
